Mesothelioma Trial, Recruiting (NCT06031636)

Mesothelioma Trial, Recruiting NCT06031636 Sponsor: Tianjin Medical University Second Hospital Condition: Mesothelioma

Printed from Voxsanity (voxsanity.com.au) — NCT06031636 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Mesothelioma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 75 years old (including those ages exactly)
You have been diagnosed with late-stage mesothelioma (a type of cancer affecting the lining of the lungs or chest) and previous immunotherapy treatment has not worked
You (or your legal representative) are able to understand and sign a consent form agreeing to take part
You have at least one tumour large enough to be seen on a scan and that can safely receive a direct injection into it or into the chest cavity
You are well enough to carry out basic daily activities, with little to no limitation (confirm with trial site)

Who may not be able to join:

The doctors running the study think you may not be able to attend regular follow-up appointments or provide ongoing information
You have any serious health conditions that are not under control, such as severe mental health, nerve, heart, or breathing problems
You have any known reasons why you cannot receive the treatment drugs used in this trial, such as the oncolytic adenovirus or certain immunotherapy medicines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-022-88326385

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06031636

Sponsor: Tianjin Medical University Second Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Mesothelioma

Trial contact: +86-022-88326385

More information: https://clinicaltrials.gov/study/NCT06031636

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 75 years old (including those ages exactly)
You have been diagnosed with late-stage mesothelioma (a type of cancer affecting the lining of the lungs or chest) and previous immunotherapy treatment has not worked
You (or your legal representative) are able to understand and sign a consent form agreeing to take part
You have at least one tumour large enough to be seen on a scan and that can safely receive a direct injection into it or into the chest cavity
You are well enough to carry out basic daily activities, with little to no limitation (confirm with trial site)

Who may not be able to join:

The doctors running the study think you may not be able to attend regular follow-up appointments or provide ongoing information
You have any serious health conditions that are not under control, such as severe mental health, nerve, heart, or breathing problems
You have any known reasons why you cannot receive the treatment drugs used in this trial, such as the oncolytic adenovirus or certain immunotherapy medicines (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Tianjin Medical University Second Hospital

Registry

ClinicalTrials.gov

Start date

20 July 2023

Est. completion

31 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR(Objective Response Rate); DCR(Disease Control Rate)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov